Can a Hong Kong-Approved Drug Access China’s Greater Bay Area Without Macau Registration?

Short answer: yes. An eligible drug already registered and marketed in Hong Kong may access designated hospitals in Mainland China’s Greater Bay Area without obtaining a separate Macau registration or full national NMPA approval.

However, Hong Kong approval does not create automatic or unrestricted Mainland market access. The product must still satisfy the Greater Bay Area’s clinical-need requirements, obtain sponsorship from a designated hospital and receive Guangdong approval for importation and institutional use.

The key rule: Hong Kong or Macau—not both

The applicable cities are Guangzhou, Shenzhen, Zhuhai, Foshan, Huizhou, Dongguan, Zhongshan, Jiangmen and Zhaoqing.

The legal standard is disjunctive: a drug may qualify through Hong Kong or Macau. A manufacturer whose drug already has a valid Hong Kong registration generally does not need to obtain a duplicative Macau registration merely to establish GBA eligibility. This is confirmed by both the current Guangdong regulation and the Hong Kong Drug Office’s description of the program.

The pathway is now well established. As of July 31, 2026, the Hong Kong Drug Office reported that 77 drugs and 95 medical devices had received approval for use through the program across 71 designated medical institutions.

What Hong Kong approval does—and does not—provide

A Hong Kong registration satisfies an important threshold requirement, but it is not equivalent to an NMPA marketing authorization.

The GBA pathway provides:

• Product-specific access through approved hospitals;
• Importation before full Mainland China registration;
• Treatment of patients meeting the approved clinical-need criteria;
• A potential platform for collecting compliant real-world evidence.

It does not provide:

• General commercial distribution throughout China;
• Automatic inclusion in every GBA hospital;
• Permission to sell through retail pharmacies or ordinary wholesalers;
• Automatic reimbursement;
• Unrestricted use outside the approved indication or hospital protocol;
• A national Chinese marketing authorization.

Each product still requires an application led by a designated medical institution. The hospital must substantiate the clinical need, intended patient population, expected usage, safety controls, ethics review and relevant treatment protocols.

How the process generally works

1. Confirm the Hong Kong regulatory status

The first step is to verify that the exact drug, strength, dosage form, manufacturer and presentation hold a current Hong Kong registration and remain lawfully marketed.

A registration covering a different manufacturing site, formulation or package may not support the proposed GBA supply without further analysis.

2. Confirm the commercial and authorization chain

The Hong Kong certificate alone does not grant another company commercial rights.

The parties should establish a documented chain connecting:

• The product owner or marketing authorization holder;
• The Hong Kong registration holder;
• The manufacturer;
• The company authorized to develop the GBA opportunity;
• The qualified importer and distributor;
• The sponsoring GBA hospital.

If the Hong Kong registration is held by an existing distributor, the manufacturer must determine whether that distributor’s rights extend into the Mainland GBA or whether the manufacturer can authorize a separate partner. Regulators and hospitals typically require documentary evidence, not merely a verbal explanation of the corporate relationships.

3. Secure a designated hospital sponsor

The applicant is the designated GBA medical institution—not the manufacturer or distributor acting alone.

The hospital evaluates the product’s clinical necessity, identifies the target patients and indication, prepares its clinical-use and risk-management procedures and completes the required ethics and informed-consent work.

A commercially interested manufacturer without a sponsoring hospital does not yet have an actionable GBA application.

4. Assemble the product and hospital documentation

For a straightforward Hong Kong-approved product, ACA Pharma’s local regulatory team often summarizes the manufacturer-facing starting package as:

One certificate, two supporting letters and the Hong Kong-approved packaging.

The certificate is the Hong Kong approval evidence. The supporting letters generally establish the relevant authorization and regulatory or commercial relationships. The exact letters depend on how the marketing authorization holder, manufacturer and distribution rights are structured.

That shorthand should not be mistaken for the complete hospital submission. The broader file may also include:

• Hong Kong registration and current marketing evidence;
• Manufacturer and marketing authorization holder documentation;
• Authorization letters and evidence connecting the relevant entities;
• Hong Kong packaging, label and package insert;
• Product quality and safety information;
• Proposed indication, patient population and estimated demand;
• Clinical-need and available-alternative analysis;
• Hospital ethics approval and informed-consent materials;
• Risk-management, pharmacovigilance and emergency procedures;
• Importer, distributor, storage and traceability documentation.

Operationally, using the existing Hong Kong package can avoid creating a separate Macau presentation solely for GBA access, provided the supplied product remains consistent with the approved Hong Kong presentation and satisfies the applicable import and labeling requirements.

5. Obtain Guangdong approval and import through a qualified operator

Once a complete application is accepted, the statutory review period depends on whether the product is already included in the applicable GBA directory:

• Directory product: five working days for the health authority’s review, followed by five working days for the drug regulator’s decision.
• Non-directory product: ten working days for each authority, or twenty working days in total, excluding expert-review time.

These are regulatory review periods after formal acceptance—not guaranteed end-to-end project timelines. Hospital selection, document preparation, translations, clinical review and contract execution frequently take longer.

The designated hospital must appoint a properly qualified company to procure, import and distribute the product with full traceability. Use remains limited to the approved institution and medical purpose.

Is Macau registration ever necessary?

Not solely to establish GBA eligibility when a usable Hong Kong approval already exists.

Macau registration may still be strategically useful where:

• The product has no Hong Kong approval;
• The Hong Kong certificate holder or distributor will not cooperate;
• Existing Hong Kong rights restrict a separate GBA appointment;
• The manufacturer wants ordinary commercial access within Macau;
• A Macau regulatory asset would provide a cleaner, independently controlled route;
• The Hong Kong-approved presentation is unavailable or unsuitable for supply.

Where the product is already approved in Hong Kong and the authorization chain is available, pursuing a separate Macau registration solely to reach the GBA may add unnecessary time, expense and duplication—particularly for older medicines, shortage products, orphan drugs and other low-volume therapies.

Can the Hong Kong approval also facilitate use in Macau?

Potentially, yes—but this is a separate process from GBA access.

Macau maintains a prior-authorization process for importing western medicines. Its published requirements include a registration certificate from the competent authority in the country or jurisdiction of origin or export, a manufacturing authorization, authorization from the manufacturer or marketing authorization holder, quality documents, a packaging sample and the package insert.

Macau’s official service standard states that prior authorization may be issued within three working days after receipt of a complete application, although documentation for a first import must be submitted in advance. Product-specific confirmation from Macau’s Pharmaceutical Administration Bureau remains essential. Macao SAR Government import requirements

The practical conclusion

A manufacturer does not need approvals in both Hong Kong and Macau to pursue the GBA pathway.

If the exact drug is already registered and marketed in Hong Kong, that approval can ordinarily serve as the regulatory foundation for a GBA application. The real work then shifts to hospital sponsorship, clinical-need justification, authorization documents, compliant importation and sustainable pricing.

The distinction is simple:

Hong Kong approval can establish eligibility. The designated hospital application and Guangdong approval create actual GBA access.

ACA Pharma works with manufacturers to assess existing Hong Kong approvals, resolve authorization chains, identify appropriate hospitals and manage the regulatory, importation, distribution and commercialization process across the Greater Bay Area.

Contact ACA Pharma to evaluate whether an existing Hong Kong registration can support GBA access without a separate Macau filing.

This article provides general regulatory and commercial information as of September 2026. Eligibility and documentation requirements should be confirmed for each product and supply structure.